Research
Metabolic adaptation
Orforglipron treatment resulted in significant improvements in waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels compared to placebo.
Orforglipron may improve several cardiovascular and metabolic risk factors in obese adults.
StrongSupportsmedium confidence
Waist circumference, systolic blood pressure, triglyceride levels, and non-HDL cholesterol levels significantly improved with orforglipron treatment as compared with placebo.
Why this rating
Based on a phase 3 randomized controlled trial design.
Source
Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment
Sean Wharton et al. · New England Journal of Medicine · 2025
rct · n=3127Cited 69×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →